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EDITORIAL
Vasculopathy and renal injury in lupus erythematosus: Does
shedding of the endothelial protein C receptor play a role?
Systemic lupus erythematosus (SLE) is a potentially
fatal, autoimmune disease that affects about 1.4 million
Americans, including 1 in 250 African American women
between the ages of 18 and 65. In the past several decades,
the prognosis for patients with SLE has greatly improved,
with a current 10-year survival rate of close to 90% [1].
This increased survival is due, in part, to the use of steroids
and other immunosuppressants, to the success of renal
dialysis and transplantation, and to the availability of
sensitive diagnostic tests for the earlier and more accu-
rate diagnosis of SLE. Nonetheless, our understanding
of the molecular mechanisms involved in the etiology
and progression of SLE are still incomplete. SLE is con-
sidered to be a classic example of an immune-complex–
mediated disease, with manifestations in multiple systems
and organs, including joints, skin, heart, liver, lungs, blood
vessels, the gastrointestinal system, and kidneys. The
immune complexes are believed to induce microvascu-
lar injury, with concomitant thrombotic manifestations
and inflammation. Numerous autoantibodies have been
identified in SLE, including antibodies to circulating,
double-stranded DNA, presumably derived from cells
undergoing apoptosis or necrosis.
In SLE, a widespread activation of vascular endothe-
lium has been demonstrated. This is associated with ab-
normal expression of markers of activation, including
adhesion molecules such as VCAM-1, E-selectin, and in-
ducible nitric oxide synthase (iNOS) [2, 3]. This activa-
tion “primes” the vasculature for subsequent challenges
by immune complexes. In this edition of Kidney Inter-
national, Sesin et al examined circulating levels of the
endothelial protein C receptor (ECPR) in a cohort of
control patients and patients with SLE in an attempt to
correlate plasma levels of soluble EPCR (sEPCR) with
SLE disease manifestation and severity [4]. EPCR is the
endothelial cell surface receptor for protein C (PC), a
vitamin K–dependent plasma glycoprotein that is syn-
thesized in the liver in an inactive form [5]. Thrombin
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cleaves PC into its active form, APC, which acts as a po-
tent anticoagulant. The transmembrane protein throm-
bomodulin (TM) can act as a cofactor for thrombin,
consequently amplifying thrombin-mediated activation
of PC [5]. In contrast, thrombin, a critical enzyme in the
coagulation cascade, has greatly reduced procoagulant
activity when complexed with TM, and shows greatly re-
duced activity for cleavage of fibrinogen, for activation
of factor V, and for activation of platelets. Activation of
PC by the thrombin-TM complex is greatly facilitated
by the binding of PC to EPCR. EPCR is constitu-
tively expressed by endothelial cells, and is structurally
similar to the MHC complex class I/CDI family of
proteins. Activation of PC to APC by the TM-thrombin-
EPCR complex thus acts as a potent anticoagulant mech-
anism. In addition to its anticoagulant role, APC also
has potent anti-inflammatory properties; APC down-
regulates thrombin generation by affecting factors Va and
VIIIa, interfering with thrombin-induced proinflamma-
tory activities, such as platelet activation, chemotaxis of
neutrophils and monocytes, and induction of leukocyte
adhesion molecules. APC also reduces inflammation by
directly inhibiting macrophage activation. APC reduces
the expression of TNFa and tissue factor, the activation
of NF-jB, and the expression of leukocyte-endothelial
adhesion molecules by macrophages. EPCR, expressed
on the plasma membrane of endothelial cells in complex
with TM and thrombin, activates PC and concentrates
it near the surface of the vessel wall. EPCR expression
by endothelial cells is suppressed by lipopolysaccharide
(LPS), inflammatory cytokines, and thrombin [6]. Cleav-
age of EPCR from the cell surface by matrix metallo-
proteinases has also been demonstrated [7]. sEPCR has
been shown to bind to PC and APC, and to inhibit the an-
ticoagulant properties of APC. Thus, cleavage of EPCR
and its release into the circulation appears to promote
a procoagulant and potentially thrombotic pathway, as
well as inflammatory responses. The roles of APC, TM,
and EPCR in coagulation and inflammation have been
elegantly reviewed by Van de Wouwer et al [8].
Sesin et al propose that the initial “priming” of vas-
cular endothelium in SLE sensitizes the vasculature
to subsequent challenges by immune complexes. These
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challenges will then result in endothelial cell injury, with
increased shedding of EPCR, and subsequent thrombotic
diathesis and inflammation. Since vascular endothelium
is inaccessible from patients, Sesin et al also examined a
population of “circulating endothelial cells” (CECs), pu-
rified using an endothelial-specific monoclonal antibody
(P1H12, Chemicon, Temecula, CA, USA). The mean
level of sEPCR was significantly elevated in the cohort of
SLE patients compared to healthy controls. One group of
patients (28%) showed variable, but consistently substan-
tially elevated sEPCR, which was further elevated when
nephritis was present. A second group (36%) showed
moderate elevations, while the remainder showed no el-
evation. These results confirm and expand data in a pre-
vious report that sEPCR is elevated in SLE patients [9].
With regard to CECs, EPCR on the surface of CECs from
SLE patients was often reduced compared to healthy con-
trols, suggesting in vivo shedding, but an inverse correla-
tion of CEC expression of cell surface EPCR to sEPCR
was not always apparent. To determine whether the in-
flammatory cytokines, IFNc or IL-1, can induce shedding
of EPCR, they were applied to human umbilical vein
endothelial cells (HUVECs) in vitro. Shedding was in-
creased by both cytokines, and was blocked by a met-
alloproteinase inhibitor, suggesting a role for inflamma-
tory cytokines in the induction of increased sEPCR in the
plasma of SLE patients.
A novel aspect of the current study involves the analy-
sis of a single nucleotide polymorphism (SNP) in exon
4 of the EPCR gene that is associated with increased
shedding of EPCR from endothelial cells [10]. This mu-
tation (A6936G), which converts serine 219 to glycine, is
in a region of the molecule that is predicted to be close
to the plasma membrane. This may increase exposure of
the mutated site to metalloproteinases, thus increasing
the potential for shedding when protease expression is
induced, for example, in response to inflammatory cy-
tokines, such as IFNc or IL-1, as discussed above. The
high-shedding GG genotype was found to be significantly
more prevalent in SLE patients than in controls, but there
were clearly individuals with elevated sEPCR who did not
carry this G allele. As indicated by the authors, further
studies are clearly necessary to evaluate the relationship
of this SNP to the vasculopathy and nephropathy of SLE
in patient subgroups. In addition, an analysis in endothe-
lial cells of the surface expression and shedding of the
mutated, versus the normal protein, in an in vitro expres-
sion system might indicate if this mutation really increases
susceptibility to metalloprotease-mediated shedding.
Overall, this study provides interesting insight into the
role of EPCR in SLE, and suggests that elevated levels
of circulating EPCR may be an additional, independent
indicator of vasculopathy and renal injury. Measurement
of sEPCR in SLE patients may, thus, be an additional di-
agnostic marker for assessing nephropathy and vascular
damage in these patients. The suggestion that an SNP in
the EPCR gene increases susceptibility to shedding in-
duced by inflammation in a subgroup of SLE patients,
clearly merits further study. It is interesting to note that
the use of soluble fragments of EPCR to prevent or treat
inflammation has been proposed [9], raising the intrigu-
ing possibility that the increased plasma sEPCR may be
related to an attempt to limit the pathobiology of the
disease, rather than a marker of its severity. Further re-
search on the validity of sEPCR as a marker of vasculitis
and nephritis in SLE, as well as on the potential use of
soluble EPCR as a therapeutic intervention, are clearly
indicated. We look forward to evaluating these studies in
the future.
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